New bead therapy may improve liver cancer treatment after shunt procedure
NCT ID NCT07322848
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether drug-eluting bead chemoembolization (DEB-TACE) works better than conventional chemoembolization (cTACE) for liver cancer patients who have had a TIPS procedure to manage complications of cirrhosis. The study will enroll 206 participants and track survival, tumor response, and quality of life over 24 months. The goal is to find a safer and more effective treatment option for this challenging patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- drug-eluting beads loaded with epirubicin or doxorubicin
- What this could lead to
- If DEB-TACE proves better, it could become the preferred treatment for liver cancer patients who have had a TIPS procedure, offering better survival and fewer side effects.
- What could go wrong
- This is a mid-stage trial with 206 participants, so results may not apply to all patients. The altered blood flow after TIPS could still cause liver toxicity or limit effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTACE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiiated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Heart scans could flag Who's at risk after liver shunt
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test